Gabelli Funds LLC Sells 4,808 Shares of ICU Medical, Inc. $ICUI

Gabelli Funds LLC lowered its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 7.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,792 shares of the medical instruments supplier’s stock after selling 4,808 shares during the quarter. Gabelli Funds LLC’s holdings in ICU Medical were worth $8,239,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Hilton Head Capital Partners LLC acquired a new position in ICU Medical in the 4th quarter valued at $32,000. Covestor Ltd grew its holdings in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio grew its holdings in shares of ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares in the last quarter. Rockefeller Capital Management L.P. increased its position in shares of ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new position in shares of ICU Medical in the fourth quarter worth $120,000. Institutional investors own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of analyst reports. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. BTIG Research assumed coverage on shares of ICU Medical in a research report on Monday, June 15th. They issued a “buy” rating and a $170.00 target price for the company. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, KeyCorp lifted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Three investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ICU Medical presently has a consensus rating of “Buy” and a consensus price target of $172.00.

Insider Buying and Selling

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director directly owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.10% of the company’s stock.

ICU Medical Price Performance

Shares of ICUI stock opened at $161.46 on Tuesday. The business has a fifty day simple moving average of $144.98 and a 200 day simple moving average of $139.78. The company has a market cap of $4.03 billion, a P/E ratio of 87.28, a P/E/G ratio of 2.20 and a beta of 0.76. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $162.85.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts forecast that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.